The Society for Immunotherapy of Cancer’s (SITC) 36 th Annual Meeting & Pre-Conference Programs (SITC 2021) will take place on Nov. 10–14, 2021, at the Walter E. Washington Convention Center in Washington, D.C. Registration and other details will be announced soon! Thank You to Our...
11-10-2021 08:00 - 11-14-2021 12:00 ET Washington DC
Your immune system is a powerful protection mechanism that works around the clock to defend you from harmful germs and internal stresses to normal cells in the body. After years of research, doctors have found a way to unleash its cancer-fighting potential, too. Immunotherapy harnesses the power...
2020 Immunotherapy.pdf
Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient’s immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and prolonged survival in some patients. However, providing robust evidence of the...
SITC Congratulates 2020 Election Winners The Society for Immunotherapy of Cancer (SITC) is pleased to share the results of the 2020 SITC Election. The candidates who received the most votes during the election, which took place May 6-20, 2020, are: Newly Elected SITC Vice President ...
header image SITC Cancer Immunotherapy Guidelines Expert Panels are comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations,...
header image The coronavirus (COVID-19) pandemic has affected all aspects of healthcare and the oncology and immuno-oncology communities may face unique challenges in regards to patient care. As immuno-oncology practitioners treat patients during the pandemic, it has also become apparent that...
Immunotherapy has revolutionized the treatment of certain types of melanoma and other skin cancers. This guide, published by Patient Resource Publishing in partnership with the Society for Immunotherapy of Cancer (SITC), provides information on melanoma and other skin cancers, the immune system,...
2020 Immuno Melanoma-Final.pdf
Immune checkpoint inhibitors (CIs) have revolutionized treatment of advanced melanoma, leading to an emerging population of long-term survivors. Survivors’ quality of life (QOL) and symptom burden are poorly understood. The authors evaluated symptom burden and QOL in patients with advanced...
Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining...
Saturday, Oct. 31, 2020 8:00 a.m. PDT Organizers: Shailender Bhatia, MD – University of Washington Petros Grivas, MD, PhD – University of Washington Andrea M. Perdue, PA – Seattle Cancer Care Alliance ACI Seattle Program Registration Registration for the live virtual ACI Seattle...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us